<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhou X</submitter><funding>National Natural Science Foundation of China</funding><funding>National Key Research and Development Program of China</funding><pagination>e2407043</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11538650</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(41)</volume><pubmed_abstract>Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS-responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self-assembled into nanoparticles (uhOLN-NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN-NPs to form nanoparticles with hypoxic and ROS responses (</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>Self-Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments.</pubmed_title><pmcid>PMC11538650</pmcid><funding_grant_id>82171058</funding_grant_id><funding_grant_id>2021YFA1101200</funding_grant_id><funding_grant_id>2021YFA1101202</funding_grant_id><funding_grant_id>U23A20435</funding_grant_id><funding_grant_id>82271091</funding_grant_id><pubmed_authors>Ji D</pubmed_authors><pubmed_authors>Xia X</pubmed_authors><pubmed_authors>Liang G</pubmed_authors><pubmed_authors>Rong R</pubmed_authors><pubmed_authors>Xiao H</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Self-Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments.</name><description>Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS-responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self-assembled into nanoparticles (uhOLN-NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN-NPs to form nanoparticles with hypoxic and ROS responses (</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2025-04-04T03:04:43.864Z</modification><creation>2025-04-04T03:04:43.864Z</creation></dates><accession>S-EPMC11538650</accession><cross_references><pubmed>39229928</pubmed><doi>10.1002/advs.202407043</doi></cross_references></HashMap>